🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

📅 [#EVENT] – We are proud to announce that Jonathan Chriqui, Chief Business Officer at MaaT Pharma, will present our latest advancements at the BIO International Convention 2025, taking place June 16–19 in Boston, USA. 📌Don’t miss our Company Presentation: 🗓 Wednesday, June

📄 [Communiqué de Presse] – MaaT Pharma annonce aujourd’hui le dépôt de la demande d’autorisation de mise sur le marché (AMM) auprès de l’Agence européenne des médicaments (EMA) pour Xervyteg® (MaaT013) dans la maladie aiguë du greffon contre l’hôte (#aGvH). 👉 Lire le

🚨 News 🚨 On June 2, 2025, a marketing authorization application was submitted to the EU Medicines Agency for MaaT013, a pooled fecal microbiota product, for the treatment of gastrointestinal acute #GvHD. This follows positive data from the Pivotal ARES study. Read more:

💡 Have you seen this recent publication in Bone Marrow Transplantation? 🔬 📃 Improved outcomes over time in patients aged ≥60 years undergoing allogeneic hematopoietic cell transplantation for acute lymphoblastic leukemia in first complete remission: a large study by the EBMT acute leukemia

[FR] - 🌍 En cette Journée mondiale de l’environnement, MaaT Pharma publie son rapport RSE 2024 ! 🎯 Notre ambition : améliorer la santé humaine grâce au microbiote, tout en agissant en faveur de l’environnement, de nos collaborateurs et d’une gouvernance responsable. 🔬 Nous

We’re proud to announce a major expansion of EMIH, with 13 new members—from biotech companies and consultancies to patient advocacy groups—joining our growing coalition. 👉Read the press release:europeanmicrobiome.org/the-european-m…

Biothérapie : le lyonnais MaaT Pharma franchit un cap avec son traitement à base de microbiote l.latribune.fr/bMa

𝗚𝗲𝘁𝘁𝗶𝗻𝗴 𝗿𝗲𝗮𝗱𝘆 𝗳𝗼𝗿 #EHA2025 ? ⁦𝘛𝘩𝘦 𝘐𝘯𝘵𝘦𝘳𝘯𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘈𝘤𝘢𝘥𝘦𝘮𝘺 𝘧𝘰𝘳 𝘊𝘭𝘪𝘯𝘪𝘤𝘢𝘭 𝘏𝘦𝘮𝘢𝘵𝘰𝘭𝘰𝘨𝘺 (𝘐𝘈𝘊𝘏) 𝘸𝘪𝘭𝘭 𝘣𝘦 𝘢𝘤𝘵𝘪𝘷𝘦𝘭𝘺 𝘱𝘳𝘦𝘴𝘦𝘯𝘵 𝘪𝘯 𝘔𝘪𝘭𝘢𝘯 𝘸𝘪𝘵𝘩 𝘥𝘪𝘧𝘧𝘦𝘳𝘦𝘯𝘵 𝘦𝘹𝘤𝘪𝘵𝘪𝘯𝘨 𝘢𝘤𝘵𝘪𝘷𝘪𝘵𝘪𝘦𝘴.

📢 [#EHA2025] – We’re excited to join the European Hematology Association (EHA) Congress from June 12–15 in Milan, Italy! Meet our team on-site: 👨‍⚕️ Gianfranco Pittari, MD PhD, Chief Medical Officer at MaaT Pharma, 🔬 Natalia Gemperle Ortiz, MD, Global Medical Lead, 📊 Salomé

📄 [#EHA2025] – MaaT Pharma is proud to announce that updated positive data from the Early Access Program (EAP) for Xervyteg® will be presented by Prof Mohamad Mohty at the European Hematology Association (EHA) Annual Congress today. The findings validate high efficacy observed

📄 [#EHA2025] – Nous sommes fiers d’annoncer que des données actualisées positives pour le programme d’accès compassionnel pour Xervyteg® seront présentées par Prof Mohamad Mohty lors du Congrès Annuel de l’European Hematology Association (EHA). Ces résultats confirment la forte

Live at #EHA2025 - proud to see Prof. Mohty Mohamad Mohty presenting promising data for GvHD patients treated with Xervyteg!

CONGRESS | #EHA25 | PRESENTATION Mohamad Mohty Mohamad Mohty Hôpital Saint-Antoine AP-HP shares results from patients with refractory GI-aGvHD treated with MaaT013, a pooled fecal allogenic microbiotherapy, in a European EAP (n = 173). ▪️ MaaT013 was safe and highly efficacious (Day-28 GI-ORR

Here is my 10-minute summary of the key myeloma highlights from #EHA2025. Warm congratulations to all the outstanding speakers and investigators. Above all, my deepest gratitude goes to the patients and their families: your courage, trust, and participation are the true driving

💬 “These data clearly confirm the efficacy of MaaT013 in aGvHD,” said Prof. Mohty Mohamad Mohty at #EHA2025 during oral presentation. With a favorable safety profile, Xervyteg® (MaaT013) our full-ecosystem microbiotherapy is showing real promise in a high unmet need and we are

EN- 📅 [#Event] – Guilhaume Debroas, Ph.D, Head of Investor Relations at MaaT Pharma, will participate in the MID & SMALL CAPS 2025 Conference by Portzamparc, taking place on June 18-19 in Paris. 📍 Join us at the Étoile Business Center (21-25 Rue Balzac, 75008 Paris), for

📰 [#Média] - MaaT Pharma à l’honneur dans La Tribune ! Merci à Anne Taffin pour cet article qui revient sur notre demande d’autorisation de mise sur le marché auprès de l’Erin pour Xervyteg® (MaaT013), notre candidat-médicament le plus avancé dans le traitement de la maladie